Last reviewed · How we verify
Mirikizumab Test
Mirikizumab Test is a Biologic drug developed by Eli Lilly and Company. It is currently in Phase 1 development. Also known as: LY3074828.
Mirikizumab is an interleukin-23 inhibitor, a type of antibody that belongs to the drug class of inhibitors. A study (NCT03662100) was conducted by Eli Lilly and Company to evaluate the safety, tolerability, and pharmacokinetics of two formulations of Mirikizumab in healthy participants.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Mirikizumab Test |
|---|---|
| Also known as | LY3074828 |
| Sponsor | Eli Lilly and Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Mirikizumab Solution (LY3074828) in Healthy Participants (PHASE1)
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants (PHASE1)
- A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants (PHASE1)
- A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants (PHASE1)
- A Study of Mirikizumab (LY3074828) Injection in Healthy Participants (PHASE1)
- A Study of Injections of LY3074828 in Healthy Participants (PHASE1)
- A Study of LY3074828 in Healthy Participants (PHASE1)
- A Study of Two Different Formulations of LY3074828 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirikizumab Test CI brief — competitive landscape report
- Mirikizumab Test updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Mirikizumab Test
What is Mirikizumab Test?
Who makes Mirikizumab Test?
Is Mirikizumab Test also known as anything else?
What development phase is Mirikizumab Test in?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Also known as: LY3074828
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing